- Gastric cancers treated with curative intent (perioperative chemotherapy, surgery) tend to recur, with most recurrences manifesting as distant metastases.
- This multicenter European study found that more than a third of patients had recurrence, 90% distant metastasis.
Why this matters
- These authors say that multimodal treatment approaches are needed to prevent distant recurrence.
- 36.8% of patients had a recurrence at median follow-up of 27.8 months.
- 90% of recurrences were distant metastases.
- 1-year recurrence-free survival, 71.8%.
- Factors affecting recurrence (HRs; 95% CIs):
- ypN+ stage: 4.92 (3.35-7.24);
- Partial/no tumor regression: 2.63 (1.22-5.64);
- 3 vs ≥6 chemotherapy cycles: 3.04 (1.99-4.63);
- R1 resection: 1.52 (1.02-2.26); and
- Less recurrence seen with antrum tumors, intestinal tumor type, complete pathological regression after preoperative chemotherapy.
- Type of preoperative chemotherapy was not associated with recurrence-free survival.
- 408 patients with gastric adenocarcinoma, 2010-2015, treated with a minimum of preoperative chemotherapy, gastrectomy with curative intent, 18 Dutch hospitals.
- Funding: None disclosed; 1 author cites several industry funding sources.
- Many values missing for some variables (e.g., tumor regression, chemotherapy type, and cycle number).